Abstract
Bleeding, thrombotic, and platelet disorders (BTPDs) are rare but complex conditions with diverse clinical presentations that often delay accurate diagnosis. In this study, we developed an Expanded Thrombohemostasis (ExTH) gene panel comprising 130 diagnostic and risk-associated genes. This panel was applied to 747 patients and 760 controls, representing the largest genetic screening study for BTPDs in an Asian population to date. A high overall diagnostic yield of 54.8% was achieved, with mutation carriers exhibiting more severe clinical phenotypes. Notably, the diagnostic rate was significantly higher in younger individuals, underscoring the clinical value of early genetic screening. Beyond traditional Tier 1 gene panels, we identified disease-causing variants in unexpected categories in 4.28% of patients, revealing extensive genotype-phenotype overlap and advocating for a broader diagnostic approach. Some pathogenic variants exhibited normal results in conventional coagulation assays, highlighting the limitations of standard functional testing in detecting underlying genetic causes. These findings establish the ExTH gene panel as a powerful tool for comprehensive genetic diagnosis, capable of capturing clinically relevant variants that would be missed by conventional approaches. This study provides new insight into the molecular landscape of BTPDs, and supports the integration of broad gene panel testing into routine clinical workflows to improve diagnostic accuracy, risk stratification, and personalized treatment.
Introduction
Inherited bleeding, thrombotic, and platelet disorders (BTPDs) encompass a wide range of conditions, from hemophilia to deep vein thrombosis. Diagnosing these disorders is notoriously difficult due to overlapping clinical symptoms and the fact that standard functional tests, such as coagulation assays, can return normal results even in the presence of underlying genetic defects. Furthermore, most existing genetic research has focused on Western populations, leaving a significant data gap for Asian populations where the prevalence and types of genetic variants may differ. This study, published in Molecular Biomedicine, addresses these challenges by introducing a comprehensive screening tool tailored to the Chinese population.
Methods and Study Design
The researchers developed the Expanded Thrombohemostasis (ExTH) gene panel, which targets 130 genes associated with thrombohemostasis, including both established diagnostic-grade genes and candidate susceptibility genes.
The study analyzed a substantial cohort of 1,507 individuals, consisting of 747 patients (560 with thrombotic, 140 with bleeding, and 47 with platelet disorders) and 760 age- and sex-matched healthy controls. The workflow utilized high-depth Next-Generation Sequencing (NGS) on the Illumina HiSeq 4000 platform. Variants were classified as Pathogenic (PV), Likely Pathogenic (LPV), or Variants of Uncertain Significance (VUS) based on ACMG/AMP guidelines.
Key Results and Insights
The ExTH panel achieved an overall diagnostic yield of 54.8% across the patient cohort. Bleeding disorders showed the highest yield (74.3%), followed by thrombotic (50.7%) and platelet disorders (44.7%).
Several critical insights emerged from the data:
- Age of Onset Signal: Diagnostic yield was significantly higher in younger patients, reaching 85.2% in pediatric bleeding cases. This suggests that genetic factors are dominant in early-onset disease, whereas environmental factors may play a larger role in older populations.
- Genotype-Phenotype Mismatch: In 4.28% of cases, the genetic cause did not match the clinical symptoms (e.g., a patient with a thrombotic phenotype carrying a bleeding gene mutation). This highlights the limitations of narrow, phenotype-driven testing panels.
- Functional "Blind Spots": Some pathogenic variants, particularly in the PROC gene, resulted in normal protein activity levels in standard lab tests despite patients suffering from severe thrombosis. Genetic testing can thus identify risks that functional assays miss.
- Population Specificity: Common Western risk factors like Factor V Leiden were absent in this cohort. Conversely, specific mutations like PROC:p.R189W were found to be much more prevalent in the Chinese population than previously reported.
Conclusion and Future Directions
The study demonstrates that broad genetic screening identifies critical variants often missed by standard clinical tests or narrow gene panels. While limited by being a single-center study, the findings provide a robust foundation for precision diagnosis in Asian populations. Future work should focus on integrating this genetic data with multi-omics approaches and expanding to multi-center studies to further refine personalized treatment strategies for BTPDs.
Summary updated